List of Excipients in Branded Drug LOCOID LIPOCREAM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch Health US LLC	LOCOID LIPOCREAM	hydrocortisone butyrate	16781-384	BUTYLPARABEN
Bausch Health US LLC	LOCOID LIPOCREAM	hydrocortisone butyrate	16781-384	CETETH-20
Bausch Health US LLC	LOCOID LIPOCREAM	hydrocortisone butyrate	16781-384	CETOSTEARYL ALCOHOL
Bausch Health US LLC	LOCOID LIPOCREAM	hydrocortisone butyrate	16781-384	CITRIC ACID MONOHYDRATE
Bausch Health US LLC	LOCOID LIPOCREAM	hydrocortisone butyrate	16781-384	MINERAL OIL

LOCOID LIPOCREAM Excipient Strategy and Commercial Opportunities

Last updated: September 9, 2026

Locoid Lipocream is a topical prescription corticosteroid containing hydrocortisone butyrate 0.1%. Its commercial differentiation depends less on the active ingredient than on vehicle performance: emolliency, spreadability, skin feel, hydration, tolerability, and delivery of hydrocortisone butyrate into inflamed skin. The formulation uses a conventional oil-in-water emulsion with mineral oil, petrolatum, propylene glycol, fatty alcohols, glyceryl monostearate, polyethylene glycol 1000 monostearate, citrate buffer, and water.[1]

The strongest commercial opportunities are generic or authorized-generic entry, differentiated dermatology vehicles, preservative-free and low-irritancy variants, pediatric positioning, and potential lifecycle products combining hydrocortisone butyrate with modern barrier-repair excipients.

What is Locoid Lipocream and how does its formulation work?

Locoid Lipocream contains hydrocortisone butyrate 0.1%, a medium-potency topical corticosteroid. The product is indicated for corticosteroid-responsive dermatoses, including atopic dermatitis and contact dermatitis, when topical corticosteroid therapy is appropriate.[1]

The formulation is an oil-in-water cream. Its excipients provide four main functions:

Formulation function	Key excipients	Commercial effect
Oil phase and emolliency	Mineral oil, white petrolatum	Occlusion, reduced transepidermal water loss, improved dryness
Emulsion structure	Cetostearyl alcohol, glyceryl monostearate, PEG 1000 monostearate	Cream consistency, physical stability, spreadability
Humectancy and solvent function	Propylene glycol	Water retention and active-ingredient solubilization
pH control	Citric acid, sodium citrate	Buffering and product stability
Continuous phase	Purified water	Hydration and cream feel

The product label identifies cetostearyl alcohol, citric acid, glyceryl monostearate, mineral oil, polyethylene glycol 1000 monostearate, propylene glycol, purified water, sodium citrate, and white petrolatum as inactive ingredients.[1]

Why the vehicle matters clinically

Hydrocortisone butyrate is a lipophilic corticosteroid. The vehicle controls how the drug partitions between the formulation and the stratum corneum. A more occlusive system can increase hydration and may increase drug uptake, while a lighter system can improve cosmetic acceptability and adherence.

Locoid Lipocream occupies a middle position between ointments and lotions:

• It is less greasy than a petrolatum-dominant ointment.
• It provides more emolliency than a low-viscosity lotion.
• It is suitable for dry or inflamed skin where patient acceptance of an ointment may be limited.
• It is less cosmetically neutral than a gel or spray formulation.

That vehicle balance is the product’s principal commercial asset.

What excipients are protected by Locoid Lipocream?

The listed excipients are widely used pharmaceutical and cosmetic materials rather than proprietary molecules. The commercial protection is therefore more likely to arise from the complete formulation, manufacturing process, performance profile, brand recognition, and regulatory history than from ownership of individual excipients.

The formulation’s defensible technical attributes may include:

1. The specific oil-to-water ratio.
2. Droplet-size distribution and emulsion rheology.
3. Hydrocortisone butyrate particle size or dissolved-state behavior.
4. Processing temperature and homogenization conditions.
5. Active release and skin permeation characteristics.
6. Physical stability during storage.
7. Sensory properties supporting adherence.
8. Compatibility between the emulsion system and the active ingredient.

A competitor can use the same excipients while producing a materially different product. Conversely, a competitor can replace one or more excipients but still face bioequivalence and product-performance requirements.

What is the FDA regulatory status of Locoid Lipocream?

Locoid Lipocream is an FDA-approved prescription topical drug. The product is associated with hydrocortisone butyrate 0.1% and an approved new drug application, historically identified as NDA 018716 in FDA product databases.[2]

The applicable regulatory pathway for a generic cream is generally an abbreviated new drug application under section 505(j) of the Federal Food, Drug, and Cosmetic Act. A generic applicant must demonstrate pharmaceutical equivalence and bioequivalence under FDA requirements. For a topical semisolid, the regulatory burden can include comparative product characterization, in vitro release testing, and other evidence required by the FDA’s product-specific guidance and topical dermatological drug guidance.[3][4]

Can a generic change the Locoid Lipocream excipients?

Yes. A generic does not necessarily need to copy every inactive ingredient. It must meet applicable sameness, safety, quality, and equivalence requirements. Excipients that change the formulation’s microstructure, release profile, irritation potential, or permeation behavior can create regulatory risk.

The highest-risk substitutions include:

• Replacing mineral oil or petrolatum with a materially different oil phase.
• Removing propylene glycol where it contributes to active solubilization.
• Changing the emulsifier system.
• Changing pH or buffer capacity.
• Introducing a preservative into a product that is marketed as preservative-free.
• Switching from a conventional emulsion to a gel-cream or polymeric system.

A formulation that is compositionally similar but structurally different can show different in vitro release or skin permeation results.

What patent and exclusivity issues affect Locoid Lipocream?

Hydrocortisone butyrate is an established corticosteroid, and Locoid Lipocream is an older prescription product. The commercial opportunity is therefore unlikely to depend on new chemical-entity exclusivity. The relevant barriers are product-specific patents, any active Orange Book listings, regulatory exclusivity, trademarks, formulation know-how, and manufacturing capability.

The FDA Orange Book is the controlling source for listed patents and regulatory exclusivity associated with approved drugs.[5] For an older topical product, the main entry scenarios are:

Entry route	Primary barrier	Commercial implication
Conventional ANDA	Pharmaceutical equivalence and topical bioequivalence	Lowest-cost route if a suitable reference product and guidance exist
Authorized generic	Manufacturing, supply, and brand-owner agreement	Faster market access with lower development risk
505(b)(2) formulation	Clinical or bridging evidence for a modified vehicle	Supports premium differentiation but raises development cost
OTC switch	Safety, labeling, consumer-use, and self-diagnosis requirements	Large market opportunity but significant regulatory burden
New combination product	Compatibility and clinical justification	Can extend lifecycle value if disease burden supports it

A Paragraph IV strategy would depend on an applicant identifying a listed patent that it believes is invalid, unenforceable, or not infringed. For an old topical corticosteroid, formulation patents and method-of-use claims are more relevant than composition-of-matter patents. The commercial value of a Paragraph IV filing would depend on the current Orange Book record, patent expiration dates, litigation timing, and settlement terms under the Hatch-Waxman framework.[5][6]

What formulation patents and method-of-use patents could cover Locoid Lipocream?

Potential claim categories include:

Formulation patents

A formulation patent could claim:

• Hydrocortisone butyrate at a defined concentration.
• A specific oil-in-water emulsion.
• Defined ratios of mineral oil, petrolatum, glycols, and emulsifiers.
• A selected pH range.
• Droplet size or rheological parameters.
• Enhanced delivery into the stratum corneum.
• Improved stability or reduced crystallization.
• A preservative-free multidose package.

Method-of-use patents

Potential method claims could address:

• Treatment of atopic dermatitis.
• Treatment of contact dermatitis.
• Short-course treatment of inflammatory dermatoses.
• Pediatric use.
• Application to specific body sites.
• Reduced corticosteroid exposure through a defined dosing schedule.

The practical strength of these patents depends on claim breadth, written-description support, prosecution history, prior art, enablement, and whether the claims are listed in the Orange Book. Broad claims to conventional excipients are generally more vulnerable than claims tied to measurable microstructure or performance characteristics.

What commercial opportunities exist for Locoid Lipocream excipients?

1. Generic hydrocortisone butyrate cream

The most direct opportunity is a lower-cost generic cream using a closely comparable emulsion. The commercial strategy should prioritize:

• Reference-product-like sensory properties.
• Comparable active release.
• Low risk of phase separation.
• Efficient filling into tubes or pump packages.
• Reliable raw-material supply.
• Avoidance of unnecessary excipient changes.

A generic that is clinically equivalent but noticeably greasier, thinner, or harder to spread may lose pharmacy substitution or patient acceptance advantages.

2. Preservative-free or low-irritancy cream

The listed Locoid Lipocream formulation does not identify a conventional antimicrobial preservative.[1] That creates a potential positioning advantage for patients with sensitive or compromised skin. A commercial entrant could emphasize:

• Low sensitization potential.
• Reduced excipient burden.
• Fragrance-free positioning.
• Compatibility with atopic skin.
• Packaging that supports microbiological control without conventional preservatives.

The main technical challenge is maintaining microbiological quality through the product’s shelf life and in-use period.

3. Barrier-repair formulation

A next-generation product could retain hydrocortisone butyrate while adding barrier-supportive ingredients such as ceramide systems, cholesterol, fatty acids, colloidal oatmeal, or selected physiological lipids. The opportunity is strongest in atopic dermatitis, where corticosteroid treatment and barrier repair are complementary commercial concepts.

The formulation must avoid reducing corticosteroid release or creating an unstable multiphase system. A barrier-repair product may require a 505(b)(2) strategy rather than a conventional ANDA if the formulation departs materially from the reference product.

4. Improved cosmetic acceptability

The product can be differentiated through:

• Lower tackiness.
• Faster rub-in.
• Reduced white residue.
• Lower greasiness.
• Better application to hair-bearing areas.
• Pump or airless packaging.
• A lighter cream for daytime use.

These changes are commercially meaningful because adherence is heavily affected by vehicle acceptability. A premium product may justify a higher price if it improves use without compromising corticosteroid delivery.

5. Site-specific dosage forms

Hydrocortisone butyrate could be developed in alternative vehicles for:

• Scalp treatment.
• Facial use, subject to potency and safety restrictions.
• Intertriginous areas.
• Large body-surface applications.
• Pediatric use.

Potential formats include lotion, solution, foam, gel-cream, spray, and ointment. Each format has different manufacturing, stability, packaging, and regulatory requirements. A scalp solution or foam would target convenience and hair-bearing areas, while an ointment would target severe xerosis and high occlusion.

How does Locoid Lipocream compare with other topical corticosteroid vehicles?

Vehicle	Relative emolliency	Cosmetic acceptability	Typical opportunity
Ointment	High	Low to moderate	Severe dryness and maximum occlusion
Lipocream or cream	Moderate to high	Moderate to high	Broad outpatient use
Lotion	Low to moderate	High	Large areas and hair-bearing skin
Gel	Low to moderate	High	Fast drying and less greasy feel
Solution	Low	High	Scalp and hairy areas
Foam	Moderate	High	Premium convenience and scalp use

Locoid Lipocream’s commercial position is strongest where patients need more moisturization than a lotion can provide but reject the greasiness of an ointment.

What manufacturing and intellectual-property barriers exist?

The active ingredient is commercially available, but the formulation still has several manufacturing barriers:

• Consistent emulsion formation.
• Control of active distribution.
• Prevention of hydrocortisone butyrate crystallization.
• Uniform filling into tubes.
• Control of viscosity across temperature ranges.
• Long-term stability.
• Microbial quality in a water-containing product.
• Comparable in vitro release.

The most valuable know-how may be process-related rather than ingredient-related. Scale-up can change droplet size, viscosity, active distribution, and release performance even when the batch formula is unchanged.

Geographic manufacturing strategy also matters. A U.S. ANDA product requires FDA-compliant manufacturing and supply-chain controls. European or other-market versions may use different excipient specifications, packaging, or regulatory standards. Cross-border commercialization must account for differences in approved formulations, labeling, manufacturing sites, and reference-product status.

What is the revenue exposure and competitive landscape?

Locoid Lipocream revenue is not separately disclosed in the public financial reporting of its commercial stakeholders. Market value is therefore best assessed through prescription volume, generic substitution, payer reimbursement, channel access, and the size of the hydrocortisone butyrate market rather than brand-level reported revenue.

The competitive landscape includes:

• Generic hydrocortisone butyrate creams.
• Hydrocortisone butyrate ointments, lotions, and solutions.
• Other medium-potency topical corticosteroids.
• Nonsteroidal atopic dermatitis products.
• Barrier-repair moisturizers.
• Combination steroid-antimicrobial products where clinically appropriate.

The product is exposed to generic erosion if multiple suppliers achieve substitutable formulations. Brand resilience is more likely where prescribers value the vehicle, patients have stable control on the product, or the brand maintains distribution and payer advantages.

What generic launch scenarios exist for Locoid Lipocream?

Early generic entry

An early entrant may use a Paragraph IV certification if an active listed patent creates a later statutory entry date. The upside is first-mover generic economics. The risks include patent litigation, a 30-month stay, invalidity exposure, and potential settlement restrictions.[6]

At-risk launch

An applicant may launch before patent litigation is fully resolved. This can create significant damages exposure if the patent is later upheld. The strategy is generally reserved for products with a strong invalidity or non-infringement position.

Conventional post-exclusivity entry

Multiple ANDA applicants may enter after relevant patents and exclusivities expire. Price erosion would then depend on the number of suppliers, pharmacy substitution, payer formulary design, and whether the reference product retains a vehicle-based prescribing advantage.

Premium differentiated entry

A 505(b)(2) product with a materially improved vehicle could avoid direct price competition, but it would require credible clinical, regulatory, and commercial differentiation. The best targets are reduced irritation, improved adherence, pediatric usability, or better performance on the scalp and hair-bearing skin.

Key Takeaways

• Locoid Lipocream’s principal commercial asset is its vehicle, not a novel active ingredient.
• The formulation combines mineral oil, petrolatum, propylene glycol, fatty alcohols, glyceryl monostearate, PEG 1000 monostearate, citrate buffer, and water.
• The main technical risk for generic developers is matching emulsion structure, active release, stability, and sensory performance.
• Generic entry, authorized-generic supply, preservative-free positioning, barrier repair, and improved cosmetic feel are the clearest commercial opportunities.
• Formulation and process patents are more commercially relevant than composition-of-matter patents.
• Orange Book listings, current patent status, and any Paragraph IV litigation must be assessed against the live FDA record before an entry decision.
• Public financial reporting does not separately disclose Locoid Lipocream revenue.
• Biosimilar risk is not applicable because Locoid Lipocream is a conventional small-molecule topical drug, not a biologic.

FAQs

Is Locoid Lipocream a biologic subject to biosimilar competition?

No. Locoid Lipocream contains hydrocortisone butyrate, a small-molecule corticosteroid. Competition proceeds through generic and, in some circumstances, 505(b)(2) pathways rather than biosimilar approval.

Can a competitor use the same excipients as Locoid Lipocream?

Yes, subject to applicable regulatory requirements. Individual excipients such as mineral oil, petrolatum, propylene glycol, and cetostearyl alcohol are not exclusive to the brand. The complete formulation, manufacturing process, and performance profile may still create regulatory or intellectual-property barriers.

Is Locoid Lipocream stronger than hydrocortisone cream?

Locoid Lipocream contains hydrocortisone butyrate 0.1%, which is generally classified as a medium-potency topical corticosteroid. Ordinary over-the-counter hydrocortisone products usually contain hydrocortisone rather than hydrocortisone butyrate and are commonly marketed at lower potency.

Which packaging is best for a Locoid Lipocream generic?

Aluminum or laminate tubes provide familiar dispensing, low unit cost, and good barrier properties. Airless pumps may support premium positioning and reduced hand contamination but increase packaging cost and device-validation requirements.

What is the strongest lifecycle strategy for hydrocortisone butyrate?

A differentiated vehicle that improves adherence while preserving corticosteroid delivery is the strongest broad strategy. The most commercially credible options are a lighter cream, scalp-focused foam or solution, pediatric-friendly package, or barrier-repair formulation.

References

1. DailyMed. (n.d.). Locoid Lipocream: Hydrocortisone butyrate cream, 0.1% prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (2022). Topical dermatologic drug product development and abbreviated new drug application submissions: Guidance for industry. https://www.fda.gov/

4. U.S. Food and Drug Administration. (n.d.). Product-specific guidances for generic drug development. https://www.accessdata.fda.gov/scripts/cder/psg/

5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

6. U.S. Food and Drug Administration. (n.d.). Hatch-Waxman amendments and abbreviated new drug applications. https://www.fda.gov/ પાડ